Quantcast

NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow

May 13, 2013

Leading Biotechnology Manufacturer NITTO DENKO Avecia Inc. broadens its offerings with its new OliGrow service

Milford, Massachusetts (PRWEB) May 13, 2013

NITTO DENKO Avecia Inc., an industry leader in therapeutic nucleic acid manufacturing and development services, is proud to introduce a new pre-clinical oligonucleotide synthesis service, OliGrow. Combining phase appropriate quality and purity standards with a high level of customer service, the Avecia OliGrow team delivers pre-clinical oligonucleotides at μmol to mmol scales, with affordable pricing and fast turn around times.

OliGrow offers custom DNA and RNA with standard chemical modifications, along with advanced solutions for more specialized needs, including oligonucleotide conjugates and specialty amidites. Its experts operate within a dedicated facility at Avecia´s FDA- registered Cincinnati, OH plant, and use instrumentation, methods, and analytics designed for scalability and consistency throughout the development process.

As the only oligonucleotide CMO that can deliver both the first μmols of pre-clinical material and bring a program through to commercialization, Avecia OliGrow creates value for its customers by building compound knowledge from the very start, avoiding future surprises and costly technical transfers and process changes.

Dr. Marc Lemaitre, Avecia´s VP for New Businesses and Services, says the company is very proud to bring this small scale service under the same roof as the large scale, clinical productions. “Previous options to bridge the gap between pure research and clinical production in the oligo space were largely accomplished through collaborations and partnerships between multiple companies. But now are pleased to offer OliGrow as a unique, one- stop option for oligonucleotide developers.”

ABOUT NITTO DENKO Avecia Inc.

NITTO DENKO Avecia, Inc. is a drug development and manufacturing services company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan´s leading diversified materials manufacturer. Avecia is a recognized leader process development, manufacture, and related services for DNA and RNA-based therapeutics. All services are offered, from preclinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics. To see what Avecia can do for your business, visit http://www.avecia.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10715509.htm


Source: prweb



comments powered by Disqus